Security key
00461U105
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS)
CUSIP: 00461U105
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock, $0.00001 par value
- Shares outstanding
- 138,752,791
- Total 13F shares
- 50,891,008
- Share change
- -1,636,635
- Total reported value
- $58,523,068
- Put/Call ratio
- 3.3%
- Price per share
- $1.15
- Number of holders
- 76
- Value change
- -$1,742,222
- Number of buys
- 29
- Number of sells
- 50
Report period
Q3 2024
Institutions
76
Top holders
10
ACRS full security history
Newer quarter: Q4 2024
Previous quarter: Q2 2024
Aclaris Therapeutics, Inc. SEC filings
Aclaris Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00461U105
Recent filing periods:
Top shareholders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BML Capital Management, LLC |
13F
|
Company |
9.4%
|
12,988,134
|
$14,286,947 | — | 30 Jun 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.4%
|
4,687,551
|
$5,156,306 | — | 30 Jun 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
2.4%
|
3,336,850
|
$3,670,535 | — | 30 Jun 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2.4%
|
3,320,206
|
$3,652,227 | — | 30 Jun 2024 | |
| Rock Springs Capital Management LP |
13F
|
Company |
2%
|
2,753,495
|
$3,028,845 | — | 30 Jun 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
1.5%
|
2,032,155
|
$2,235,371 | — | 30 Jun 2024 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
1.4%
|
1,927,446
|
$2,120,191 | — | 30 Jun 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
1.4%
|
1,913,449
|
$2,103,000 | — | 30 Jun 2024 | |
| Trium Capital LLP |
13F
|
Company |
1.4%
|
1,892,050
|
$2,081,000 | — | 30 Jun 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1%
|
1,436,900
|
$1,580,590 | — | 30 Jun 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.8%
|
1,113,072
|
$1,224,379 | — | 30 Jun 2024 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
0.72%
|
1,000,000
|
$1,100,000 | — | 30 Jun 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.68%
|
940,752
|
$1,034,827 | — | 30 Jun 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.67%
|
923,313
|
$1,015,644 | — | 30 Jun 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.66%
|
922,200
|
$1,014,420 | — | 30 Jun 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.66%
|
916,620
|
$1,008,282 | — | 30 Jun 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.63%
|
875,216
|
$962,738 | — | 30 Jun 2024 | |
| Aldebaran Capital, LLC |
13F
|
Company |
0.62%
|
858,152
|
$943,967 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.56%
|
774,137
|
$851,714 | — | 30 Jun 2024 | |
| Samsara BioCapital, LLC |
13F
|
Company |
0.5%
|
696,171
|
$765,788 | — | 30 Jun 2024 | |
| FMR LLC |
13F
|
Company |
0.5%
|
689,353
|
$758,288 | — | 30 Jun 2024 | |
| Palo Alto Investors LP |
13F
|
Company |
0.41%
|
569,832
|
$626,815 | — | 30 Jun 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.38%
|
520,469
|
$572,516 | — | 30 Jun 2024 | |
| Acuitas Investments, LLC |
13F
|
Company |
0.33%
|
464,120
|
$510,532 | — | 30 Jun 2024 | |
| Aisling Capital Management LP |
13F
|
Company |
0.31%
|
434,455
|
$477,901 | — | 30 Jun 2024 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.28%
|
386,177
|
$424,795 | — | 30 Jun 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.24%
|
336,677
|
$370,000 | — | 30 Jun 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.24%
|
335,009
|
$368,510 | — | 30 Jun 2024 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.23%
|
312,714
|
$344,000 | — | 30 Jun 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.19%
|
264,377
|
$290,815 | — | 30 Jun 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.19%
|
260,706
|
$286,777 | — | 30 Jun 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.15%
|
206,600
|
$227,260 | — | 30 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.14%
|
196,621
|
$216,283 | — | 30 Jun 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.13%
|
186,343
|
$204,977 | — | 30 Jun 2024 | |
| Alpine Global Management, LLC |
13F
|
Company |
0.13%
|
177,909
|
$195,700 | — | 30 Jun 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.11%
|
150,700
|
$165,770 | — | 30 Jun 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.1%
|
139,400
|
$154,000 | — | 30 Jun 2024 | |
| Man Group plc |
13F
|
Company |
0.09%
|
118,459
|
$130,305 | — | 30 Jun 2024 | |
| Centiva Capital, LP |
13F
|
Company |
0.09%
|
117,966
|
$129,763 | — | 30 Jun 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.08%
|
115,580
|
$127,138 | — | 30 Jun 2024 | |
| Y-Intercept (Hong Kong) Ltd |
13F
|
Company |
0.08%
|
114,806
|
$126,287 | — | 30 Jun 2024 | |
| Point72 Asia (Singapore) Pte. Ltd. |
13F
|
Company |
0.08%
|
107,929
|
$118,722 | — | 30 Jun 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.07%
|
94,687
|
$104,156 | — | 30 Jun 2024 | |
| Marquette Asset Management, LLC |
13F
|
Company |
0.06%
|
83,979
|
$92,377 | — | 30 Jun 2024 | |
| Verition Fund Management LLC |
13F
|
Company |
0.06%
|
82,883
|
$91,171 | — | 30 Jun 2024 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.06%
|
81,005
|
$89,000 | — | 30 Jun 2024 | |
| Paloma Partners Management Co |
13F
|
Company |
0.06%
|
79,200
|
$87,120 | — | 30 Jun 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.06%
|
76,759
|
$84,435 | — | 30 Jun 2024 | |
| Deuterium Capital Management, LLC |
13F
|
Company |
0.05%
|
72,091
|
$79,300 | — | 30 Jun 2024 | |
| Engineers Gate Manager LP |
13F
|
Company |
0.04%
|
60,536
|
$66,590 | — | 30 Jun 2024 |
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q3 2024
As of 30 Sep 2024,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
76 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,891,008 shares.
The largest 10 holders included
BML Capital Management, LLC, VANGUARD GROUP INC, D. E. Shaw & Co., Inc., MILLENNIUM MANAGEMENT LLC, Rock Springs Capital Management LP, Stonepine Capital Management, LLC, ACADIAN ASSET MANAGEMENT LLC, Trium Capital LLP, BlackRock, Inc., and RENAISSANCE TECHNOLOGIES LLC.
This page lists
77
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
93
Q3 2024 holders
76
Holder diff
-17
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.